CELLASTRA INC.
Therapeutics & Pharmacogenomics
Cellastra, a Pioneer leading the Path in Stem Cell Engineering & Genomics towards Regenerative Medicine and Therapeutics.
Cellastra Inc. is a Stem Cells Therapeutics & Pharmacogenomics company that aims to develop, patent and commercialize innovative, cutting-edge technologies for developing human embryonic stem cells (hESCs) based therapeutics and research tools.
Cellastra’s Unique Assets
CellastraHSC™ lines: Cellastra's mission is to support development of the world's highest quality pluripotent stem cell lines to expedite therapeutic and research applications. These clinical grade proprietary cell lines will therefore be made available to collaborators in the biomedical industry and research laboratories under special agreements. These may involve drug discovery, regenerative medicine, neuronal diseases, diabetes, blood disorders, liver and kidney ailments, toxicology, and new anticancer agents, as well as development of animal models transplanted with human stem cells.
CellastraGenie™: Cellastra’s comprehensive Genetic Portfolio Database may become a fundamental tool in Pharmacogenomics allowing for rapid data analysis and facilitating safe, effective design of clinical trials, focusing on Personalized Medicine. This tool will provide information required for FDA approval, which requires a clonal population of stem cells for transplantations, as well as Biomarkers to establish pluripotent versus differentiated state of cells. Hence the information allows for normal Managed, Regulated use of pluripotent cells.